182 related articles for article (PubMed ID: 29540336)
1. A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Contemp Clin Trials; 2018 May; 68():67-71. PubMed ID: 29540336
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Clin Drug Investig; 2016 Dec; 36(12):985-992. PubMed ID: 27605258
[TBL] [Abstract][Full Text] [Related]
3. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
[TBL] [Abstract][Full Text] [Related]
7. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
Kinoshita Y; Miwa H; Kasugai K
Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1428-38. PubMed ID: 23912002
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
Zhuang Q; Liao A; He Q; Liu C; Zheng C; Li X; Liu Y; Wang B; Liu S; Zhang Y; Lin R; Chen H; Deng M; Tang Y; He C; Dai W; Tang H; Gong L; Li L; Xu B; Yang C; Zhou B; Su D; Guo Q; Li B; Zhou Y; Wang X; Fei S; Wu H; Wei S; Peng Z; Wang J; Li Y; Wang H; Deng T; Ding S; Li F; Chen M; Xiao Y
J Gastroenterol Hepatol; 2024 Apr; 39(4):658-666. PubMed ID: 38251791
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
Katz PO; Le Moigne A; Pollack C
Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
[TBL] [Abstract][Full Text] [Related]
12. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Labenz J; Armstrong D; Leodolter A; Baldycheva I
Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
[TBL] [Abstract][Full Text] [Related]
13. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-].
Kinoshita Y; Miwa H; Kasugai K
Nihon Shokakibyo Gakkai Zasshi; 2013 Feb; 110(2):234-42. PubMed ID: 23381211
[TBL] [Abstract][Full Text] [Related]
15. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Holtmann G; Cain C; Malfertheiner P
Gastroenterology; 1999 Jul; 117(1):11-6. PubMed ID: 10381904
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
18. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
20. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study.
Hong SJ; Park SH; Moon JS; Shin WG; Kim JG; Lee YC; Lee DH; Jang JY; Kim JJ; Lee HL; Lee SW; Hwangbo Y; Xu J; Wang B; Xue Z; Liu F; Yuan Y; Leelakusolvong S; Dy F
Gut Liver; 2016 Nov; 10(6):910-916. PubMed ID: 27282265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
